Evaluation of Alternative Site Goserelin Acetate Injection for Ovarian Function Suppression (OFS) in Local and Locally Advanced Premenopausal Hormone Receptor Positive Breast Cancer Patients
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II trial determines if giving goserelin acetate injections in the upper gluteal region is as effective for ovarian function suppression (OFS) as giving injections in the abdomen for ovarian function suppression (OFS) in premenopausal patients with hormone receptor positive breast cancer that has not spread to other parts of the body (localized) or that has spread to nearby tissue or lymph nodes (locally advanced). Goserelin acetate is a drug used to treat prostate cancer, relieve the symptoms of advanced breast cancer, and treat problems with the endometrium (lining of the uterus). Goserelin acetate initially causes the pituitary gland to make more luteinizing hormone (LH) and follicle-stimulating hormone (FSH), temporarily increasing testosterone levels in men and estrogen levels in women. With continued use, goserelin acetate lowers the amount of LH and FSH the pituitary gland releases, leading to a drop in testosterone levels in men and estrogen levels in women. Goserelin acetate may stop the growth of cancer cells that need testosterone or estrogen to grow. It is a type of hormone therapy called a luteinizing hormone-releasing hormone (LHRH) agonist. Giving goserelin acetate injections in the upper gluteal region may be as effective for OFS as giving injections in the abdomen for OFS in premenopausal patients with localized or locally advanced hormone receptor positive breast cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek od 18 do poniżej 50 lat
- •Potwierdzony histologicznie lub cytologicznie rak piersi dodatni na receptor hormonalny, stadium I-III, po zakończeniu leczenia kuracyjnego i w remisji
- •Już przyjmuje zastrzyken goserelin raz na miesiąc w brzuch przez co najmniej 6 miesięcy, razem z lekami hormonalnymi (inhibitor aromatazy lub tamoksyfen)
- •Dobre lub zadowalające ogólne samopoczucie (skala ECOG 0-2)
- •Napisana zgoda na uczestnictwo w badaniu
- •Możliwość samodzielnego wypełniania ankiet lub z pomocą
- •Test ciążowy ujemny (w ciągu 14 dni przed rejestracją)
- •Zgoda na stosowanie antykoncepcji podczas badania i przez 3 miesiące po jego zakończeniu
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 50 Years
- Last updated (source)
- July 8, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (1)
Mayo Clinic in Rochester
Rochester, United States
Trial contact
Clinical Trials Referral Office
Cancer Center Clinical Trials
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/9/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.